[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.0.26. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
April 1991

A Cytotoxic T-Lymphocyte Clone Derived From Mice With Progressively Growing Tumors

Author Affiliations

From the Massey Cancer Center (Drs Hoover, Frank, Susskind, and Bear and Mr Inge) and Departments of Surgery (Drs Hoover, Frank, Susskind, and Bear) and Microbiology and Immunology (Drs Monaco, Susskind, and Bear and Mr Inge), Medical College of Virginia, Virginia Commonwealth University, Richmond; and University of Calgary, Alberta (Dr McKinnon).

Arch Surg. 1991;126(4):447-452. doi:10.1001/archsurg.1991.01410280045006
Abstract

• Tumor-specific T-cell clones were derived from spleen cells of mice bearing a syngeneic PHS-5 tumor (a P815 mastocytoma mutant). Cells were expanded in vitro and characterized and assayed for activity against the relevant tumor in vivo. Clone cells were CD4−, CD8+ T lymphocytes, as determined by fluorescence activated cell sorting analysis and were specifically cytotoxic against P815 tumor cells in vitro, as shown in chromium 51 release assays. These cells require both antigen and interleukin 2 to proliferate; neither alone is sufficient, even with the addition of interleukin 1. In an experimental P815 liver metastasis model, the adoptive transfer of GD11 or GD11.17 clone cells and injection of recombinant interleukin 2 (7500 U intraperitoneally) 3 days after infusion of tumor cells reduced the number of tumor nodules, while the adoptive transfer of lymphokine-activated killer cells was ineffective.

(Arch Surg. 1991;126:447-452)

×